R
Rallybio Corporation (RLYB)
8.22
0.00 (0.00%)
Get all premium features to the best stock analysis tool
8.22
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 14.50 | 6.05 | 10 | |
| Quick ratio | 14.50 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 636K | 858K | 858K |
| Gross Profit | -167K | -150K | 505K | 766K | 766K |
| Operating Income | -68M | -79M | -60M | -28M | -30M |
| Net Income | -67M | -75M | -58M | -9M | -9M |
| EBITDA | -68M | -79M | -60M | -28M | -30M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -100 | 28.57 | 5.5 |
| Next quarter | -100 | 27.27 | 5.5 |
| Current year | N/A | N/A | 1.0 |
| Next year | N/A | -113.33 | 1.0 |
| Weighted average score | 3.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 4.72 | -136.53 | 263.64 | 28.56 | 6.3 |
| Y/Y | 484.21 | 47.01 | 238.46 | 52.56 | 10 |
| 3y average | 677.64 | 31.71 | 19.84 | 17.54 | 9.5 |
| 5y average | 806.18 | -4.87 | 8.7 | -15.83 | 4.5 |
| Weighted average score | 7.6 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $31.4M significantly exceed its total debt $176.0K, ensuring strong financial flexibility
Total current assets $61.3M exceed Total current liabilities $4.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$4.7M limits the company's ability to reinvest or pay down debt